SK Bioscience (KRX:302440) will supply 750,000 doses of influenza vaccines to Southeast Asia and Latin America in the first half of 2025, the South Korean biotechnology company said Wednesday.
This marks the company's second flu vaccine export for use in the Southern Hemisphere, following its initial shipment to Thailand last year. SK Bioscience is also boosting its global expansion with in-house vaccines for influenza, varicella, shingles, and typhoid, the release said.
Shares of SK Bioscience rose 4% at market close on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.